Earnings Are Growing at Shanghai Kehua Bio-EngineeringLtd (SZSE:002022) but Shareholders Still Don't Like Its Prospects
Earnings Are Growing at Shanghai Kehua Bio-EngineeringLtd (SZSE:002022) but Shareholders Still Don't Like Its Prospects
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been particularly tough on longer term Shanghai Kehua Bio-Engineering Co.,Ltd (SZSE:002022) shareholders. Unfortunately, they have held through a 57% decline in the share price in that time. The more recent news is of little comfort, with the share price down 38% in a year. Furthermore, it's down 14% in about a quarter. That's not much fun for holders. But this could be related to the weak market, which is down 8.2% in the same period.
投资股票不可避免地意味着买入一些表现不佳的公司。但是从长远来看,过去三年尤其艰难。 上海科华生物工程有限公司, Ltd (深圳证券交易所:002022) 股东。不幸的是,在那段时间里,他们的股价一直下跌了57%。最近的消息并不令人安慰,股价在一年内下跌了38%。此外,它在大约一个季度内下跌了14%。对于持有者来说,这没什么好玩的。但这可能与疲软的市场有关,同期下跌了8.2%。
After losing 8.1% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.
在上周下跌8.1%之后,值得调查该公司的基本面,以了解我们可以从过去的表现中推断出什么。
See our latest analysis for Shanghai Kehua Bio-EngineeringLtd
查看我们对上海科华生物工程有限公司的最新分析
In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
在他的文章中 格雷厄姆和多兹维尔的超级投资者 沃伦·巴菲特描述了股价如何并不总是合理地反映企业的价值。考虑市场对公司的看法发生了怎样的变化的一种不完美但简单的方法是将每股收益(EPS)的变化与股价走势进行比较。
Although the share price is down over three years, Shanghai Kehua Bio-EngineeringLtd actually managed to grow EPS by 54% per year in that time. This is quite a puzzle, and suggests there might be something temporarily buoying the share price. Or else the company was over-hyped in the past, and so its growth has disappointed.
尽管股价在三年内下跌,但在这段时间里,上海科华生物工程有限公司的每股收益实际上每年增长54%。这是一个很大的难题,这表明可能有一些因素暂时提振了股价。或者,该公司过去曾被过度炒作,因此其增长令人失望。
Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics.
由于每股收益的变化似乎与股价的变化无关,因此值得一看其他指标。
Given the healthiness of the dividend payments, we doubt that they've concerned the market. We like that Shanghai Kehua Bio-EngineeringLtd has actually grown its revenue over the last three years. If the company can keep growing revenue, there may be an opportunity for investors. You might have to dig deeper to understand the recent share price weakness.
鉴于股息支付的健康性,我们怀疑它们是否引起了市场的担忧。我们喜欢上海科华生物工程有限公司在过去三年中其收入实际上有所增长。如果公司能够继续增加收入,那么投资者可能会有机会。您可能需要更深入地了解最近的股价疲软。
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
公司的收入和收益(随着时间的推移)如下图所示(点击查看确切数字)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231021/0-e903a74925bf83eff068061900382247-0-dbbc3de42dbeb26fe0ba0634191695d6.png/big)
You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.
您可以在此看到其资产负债表是如何随着时间的推移而增强(或减弱)的 免费的 交互式图形。
What About Dividends?
分红呢?
It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for Shanghai Kehua Bio-EngineeringLtd the TSR over the last 3 years was -53%, which is better than the share price return mentioned above. This is largely a result of its dividend payments!
重要的是要考虑任何给定股票的股东总回报以及股价回报。股东总回报率是一种回报计算方法,它考虑了现金分红的价值(假设收到的任何股息都被再投资)以及任何贴现的融资和分拆的计算价值。因此,对于支付丰厚股息的公司来说,股东总回报率通常比股价回报率高得多。我们注意到,上海科华生物工程有限公司过去三年的股东总回报率为-53%,好于上述股价回报率。这在很大程度上是其股息支付的结果!
A Different Perspective
不同的视角
While the broader market lost about 5.8% in the twelve months, Shanghai Kehua Bio-EngineeringLtd shareholders did even worse, losing 34% (even including dividends). Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 1.4% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Shanghai Kehua Bio-EngineeringLtd better, we need to consider many other factors. For example, we've discovered 1 warning sign for Shanghai Kehua Bio-EngineeringLtd that you should be aware of before investing here.
尽管整个市场在十二个月内下跌了约5.8%,但上海科华生物工程有限公司的股东表现更糟,下跌了34%(甚至包括股息)。话虽如此,在下跌的市场中,一些股票不可避免地会被超卖。关键是要密切关注基本面发展。遗憾的是,去年的业绩结束了糟糕的表现,股东们在五年内每年面临1.4%的总亏损。我们意识到,罗斯柴尔德男爵曾表示,投资者应该 “在街上流血时买入”,但我们提醒说,投资者应首先确保他们购买的是高质量的企业。从长远来看,追踪股价表现总是很有意思的。但是,为了更好地了解上海科华生物工程有限公司,我们需要考虑许多其他因素。例如,我们发现 上海科华生物工程有限公司有 1 个警告标志 在这里投资之前,你应该注意这一点。
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
对于那些喜欢寻找的人 获胜的投资 这个 免费的 最近进行内幕收购的成长型公司名单可能只是门票。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?担心内容吗? 取得联系 直接和我们在一起。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。 我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。简而言之,华尔街在上述任何股票中都没有头寸。